In 2022, the FDA issued emergency use authorization for administration of Evusheld, comprised of two monoclonal antibody medications that help minimize the risk of severe COVID-19 disease in immunocompromised patients. Once Evusheld became available, nurses at a large academic medical center researched the medication and conducted education on safety, efficacy, and administration. Shortly thereafter, administration of Evusheld was implemented within the existing special pathogens clinic and offered to physician-identified patients with the highest risk of severe COVID-19 infection for whom the vaccine would be ineffective. This session discusses the patient response and efficacy in preventing COVID-19 infection in the patients who have received it.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 4/15/2025.
Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online nursing continuing professional development (NCPD) evaluation. You will be able to print your NCPD certificate at any time after you complete the evaluation.
Disclosure of relevant financial relationships with ineligible companies (planners, faculty/speakers, reviewers):
Planning Committee Disclosures:
There are no Planning Committee disclosures to declare.
Speaker Disclosures:
There are no speaker disclosures to declare.
Commercial Support:
No commercial support declared.
Accreditation Statement:
This educational activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the American Academy of Ambulatory Care Nursing (AAACN).
Anthony J. Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
AAACN is a provider approved by the California Board of Registered Nursing, provider number CEP 5366.
Learning Outcome:
After completing this learning activity, the participant will be able to describe the role and efficacy of a monoclonal antibody medication in the prevention of severe cases of COVID-19 in immunocompromised and at-risk patients.
- 212_BrewerUpdated: March 28, 2023
